Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 161

Sort by

Sort Order Select

Journal Articles

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Blood (2024) 144 (5): 510–524.

https://doi.org/10.1182/blood.2023021990

Published: 2024

Includes: Supplemental data

Journal Articles

Transcriptional Changes in Patients with CLL Starting Venetoclax Therapy Identifies Inflammatory and Adaptive Stress Responses

Layla M. Saleh, Maissa Mhibik, Jonathan Chen, Clare Sun, Christopher Pleyer, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 4196.

https://doi.org/10.1182/blood-2023-190376

Published: 2023

Journal Articles

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Andy Itsara, Clare Sun, Emily Bryer, Inhye E Ahn, Susan Soto, Hao-Wei Wang, Constance M. Yuan, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 201.

https://doi.org/10.1182/blood-2023-182397

Published: 2023

Journal Articles

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Blood (2023) 142 (Supplement 1): 4463.

https://doi.org/10.1182/blood-2023-179872

Published: 2023

Journal Articles

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

Clare Sun, Raghuveer Mali, Rachel Kositsky, Xin Tian, Hannah Tomczak, Barrett Nuttall, Rafael White, Simon Rule, Veerendra Munugalavadla, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 1891.

https://doi.org/10.1182/blood-2023-178819

Published: 2023

Journal Articles

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Blood (2023) 141 (13): 1584–1596.

https://doi.org/10.1182/blood.2022016934

Published: 2023

Includes: Supplemental data

Journal Articles

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 2329–2332.

https://doi.org/10.1182/blood-2022-164772

Published: 2022

Journal Articles

Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib

Andy Itsara, Clare Sun, Inhye E. Ahn, Susan Soto, Douglas Rosing, Mark Haigney, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 4169–4170.

https://doi.org/10.1182/blood-2022-159716

Published: 2022

Journal Articles

Establishment and Characterization of Mouse Models with Primary and Acquired BTK Inhibitor Resistance

Laura Polcik, Svenja Dannewitz Prosseda, Chingiz Underbayev, Geoffroy Andrieux, Lixia Li, Danielle-Justine Danner, Driti Ashok, Sandra Kissel, Sara Parsa, Natalie Koehler, Melanie Börries, Justus Duyster, Elena Bibikova, Adrian Wiestner, Tanja Nicole Hartmann

Blood (2022) 140 (Supplement 1): 4109–4110.

https://doi.org/10.1182/blood-2022-164662

Published: 2022

Journal Articles

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL

Emily Bryer, Shira Paul, Jonathan Chen, Christopher Pleyer, Adrian Wiestner, Clare Sun

Blood (2022) 140 (Supplement 1): 9896–9897.

https://doi.org/10.1182/blood-2022-162365

Published: 2022

Journal Articles

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression Free Survival on BTK Inhibitor Therapy

Anfal Alsadhan, Jonathan Chen, Clare Sun, Chingiz Underbayev, Elena Bibikova, Tanja Nicole Hartmann, Maissa Mhibik, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 6004–6005.

https://doi.org/10.1182/blood-2022-163370

Published: 2022

Journal Articles

Ibrutinib-Associated Sudden Death in Patients with CLL

Emily Bryer, Andy Itsara, Inhye E. Ahn, Beth Kozel, Cody Peer, William D. Figg, Adrian Wiestner, Clare Sun

Blood (2022) 140 (Supplement 1): 4133–4134.

https://doi.org/10.1182/blood-2022-160397

Published: 2022

Journal Articles

Targeting C3d in Combination with Daratumumab: a Strategy to Enhance Therapeutic Potential in Multiple Myeloma

Sivasubramanian Baskar, Haiyong Peng, Christoph Rader, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 9989–9990.

https://doi.org/10.1182/blood-2022-166681

Published: 2022

Journal Articles

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Ziran Zhao, McKensie Collins, Clare Sun, Adrian Wiestner, J. Joseph Melenhorst

Blood (2022) 140 (Supplement 1): 10255–10256.

https://doi.org/10.1182/blood-2022-158614

Published: 2022

Journal Articles

Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression

Clare Sun, Melih Acar, David Jenkins, Barrett Nuttall, Rafael White, Veerendra Munugalavadla, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 9847–9848.

https://doi.org/10.1182/blood-2022-159525

Published: 2022

Journal Articles

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

Maissa Mhibik, Erika M. Gaglione, David Eik, Ellen K. Kendall, Amy Blackburn, Keyvan Keyvanfar, Maria Joao Baptista, Inhye E. Ahn, Clare Sun, Junpeng Qi, Christoph Rader, Adrian Wiestner

Blood (2021) 138 (19): 1843–1854.

https://doi.org/10.1182/blood.2020009686

Published: 2021

Includes: Supplemental data

Journal Articles

Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial

Inhye E. Ahn, Amy S. Ruppert, Adrian Wiestner, James S. Blachly, John C. Byrd, Richard M. Stone, Sumithra J Mandrekar, Jennifer A. Woyach

Blood (2021) 138 (Supplement 1): 2642.

https://doi.org/10.1182/blood-2021-153822

Published: 2021

Journal Articles

Humoral and Cellular Immunogenicity of COVID-19 Vaccinations in Patients with CLL

Clare Sun, Erika M Gaglione, Lauren T Vaughn, Rui Mu, Chingiz Underbayev, Jonathan Chen, Christopher Pleyer, Adrian Wiestner

Blood (2021) 138 (Supplement 1): 3724.

https://doi.org/10.1182/blood-2021-148887

Published: 2021

Journal Articles

Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine

Christopher Pleyer, Kerry J Laing, Mir Ali, Christopher L McClurkan, Susan Soto, Inhye E. Ahn, Pia Nierman, Emeline Maddux, Jennifer Lotter, Jeanine Superata, Xin Tian, Erika M Gaglione, Adrian Wiestner, Jeffrey Cohen, David M Koelle, Clare Sun

Blood (2021) 138 (Supplement 1): 1556.

https://doi.org/10.1182/blood-2021-148539

Published: 2021

Journal Articles

MARCKS affects cell motility and response to BTK inhibitors in CLL

Blood (2021) 138 (7): 544–556.

https://doi.org/10.1182/blood.2020009165

Published: 2021

Includes: Supplemental data

NARROW

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Transcriptional Changes in Patients with CLL Starting Venetoclax Therapy Identifies Inflammatory and Adaptive Stress Responses

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib

Establishment and Characterization of Mouse Models with Primary and Acquired BTK Inhibitor Resistance

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression Free Survival on BTK Inhibitor Therapy

Ibrutinib-Associated Sudden Death in Patients with CLL

Targeting C3d in Combination with Daratumumab: a Strategy to Enhance Therapeutic Potential in Multiple Myeloma

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial

Humoral and Cellular Immunogenicity of COVID-19 Vaccinations in Patients with CLL

Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine

MARCKS affects cell motility and response to BTK inhibitors in CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only